Charles M. Rudin

86.3k total citations · 23 hit papers
458 papers, 31.1k citations indexed

About

Charles M. Rudin is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Charles M. Rudin has authored 458 papers receiving a total of 31.1k indexed citations (citations by other indexed papers that have themselves been cited), including 279 papers in Oncology, 201 papers in Molecular Biology and 176 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Charles M. Rudin's work include Lung Cancer Research Studies (183 papers), Lung Cancer Treatments and Mutations (155 papers) and Neuroendocrine Tumor Research Advances (73 papers). Charles M. Rudin is often cited by papers focused on Lung Cancer Research Studies (183 papers), Lung Cancer Treatments and Mutations (155 papers) and Neuroendocrine Tumor Research Advances (73 papers). Charles M. Rudin collaborates with scholars based in United States, United Kingdom and Canada. Charles M. Rudin's co-authors include John T. Poirier, Christine L. Hann, Craig B. Thompson, Lauren A. Byers, Julien Sage, Jennifer A. Low, Corinne Faivre‐Finn, Mark G. Kris, Triparna Sen and Natasha Rekhtman and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Charles M. Rudin

443 papers receiving 30.6k citations

Hit Papers

Akt Stimulates Aerobic Glycolysis in Cancer Cells 2004 2026 2011 2018 2004 2012 2021 2009 2009 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Akt Stimulates Aerobic Glycolysis in Cancer Cells
    2004 1.2k citations Charles M. Rudin et al. Cancer Research profile →
  2. Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
    2012 1.0k citations Aleksandar Sekulić, Michael R. Migden et al. New England Journal of Medicine profile →
  3. Small-cell lung cancer
    2021 860 citations Charles M. Rudin et al. profile →
  4. Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma
    2009 833 citations Daniel D. Von Hoff, Patricia LoRusso et al. New England Journal of Medicine profile →
  5. Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449
    2009 761 citations Charles M. Rudin, Christine L. Hann et al. New England Journal of Medicine profile →
  6. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
    2019 718 citations Charles M. Rudin, John T. Poirier et al. profile →
  7. Genetic Variants in the UDP-glucuronosyltransferase 1A1 Gene Predict the Risk of Severe Neutropenia of Irinotecan
    2004 695 citations Charles M. Rudin et al. profile →
  8. Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma
    2009 670 citations Robert L. Yauch, Christine L. Hann et al. profile →
  9. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
    2020 491 citations Charles M. Rudin et al. profile →
  10. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer
    2016 486 citations Ai Ni, Jamie E. Chaft et al. profile →
  11. Small cell lung cancer: Where do we go from here?
    2014 453 citations Charles M. Rudin et al. profile →
  12. Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping
    2015 423 citations Paul K. Paik, Alexander Drilon et al. Cancer Discovery profile →
  13. CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future
    2020 354 citations Charles M. Rudin et al. profile →
  14. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
    2016 327 citations Alexander Drilon, Natasha Rekhtman et al. profile →
  15. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets
    2016 325 citations Natasha Rekhtman, Matthew D. Hellmann et al. Clinical Cancer Research profile →
  16. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
    2021 321 citations Benjamin Besse, Charles M. Rudin et al. profile →
  17. Lineage plasticity in cancer: a shared pathway of therapeutic resistance
    2020 310 citations Joseph M. Chan, Helena A. Yu et al. profile →
  18. SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization
    2020 301 citations John T. Poirier, Charles M. Rudin et al. profile →
  19. High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden
    2019 289 citations Darragh Halpenny, Charles M. Rudin et al. Clinical Cancer Research profile →
  20. Regenerative lineages and immune-mediated pruning in lung cancer metastasis
    2020 251 citations Natasha Rekhtman, John T. Poirier et al. profile →
  21. TMEM41B Is a Pan-flavivirus Host Factor
    2020 136 citations Charles M. Rudin, John T. Poirier et al. profile →
  22. Cellular ATP demand creates metabolically distinct subpopulations of mitochondria
    2024 102 citations Charles M. Rudin et al. Nature profile →
  23. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer
    2023 89 citations Charles M. Rudin, Christine L. Hann et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Charles M. Rudin United States 86 17.2k 15.7k 7.6k 6.4k 4.6k 458 31.1k
Godefridus J. Peters Netherlands 92 18.0k 1.0× 16.5k 1.1× 5.4k 0.7× 2.1k 0.3× 5.6k 1.2× 854 35.0k
Manuel Hidalgo United States 85 12.5k 0.7× 18.5k 1.2× 7.0k 0.9× 2.2k 0.3× 7.4k 1.6× 448 29.7k
Daniel D. Von Hoff United States 91 19.7k 1.1× 23.6k 1.5× 6.7k 0.9× 4.1k 0.6× 8.3k 1.8× 821 44.9k
Ming‐Sound Tsao Canada 98 16.5k 1.0× 15.3k 1.0× 13.8k 1.8× 2.1k 0.3× 8.3k 1.8× 653 37.2k
Fadlo R. Khuri United States 85 14.7k 0.9× 9.9k 0.6× 5.6k 0.7× 1.9k 0.3× 4.5k 1.0× 486 27.1k
Aldo Scarpa Italy 77 11.9k 0.7× 17.2k 1.1× 4.4k 0.6× 9.3k 1.4× 9.5k 2.0× 609 32.9k
Richard A. Scolyer Australia 84 13.3k 0.8× 21.3k 1.4× 3.8k 0.5× 4.1k 0.6× 4.3k 0.9× 707 30.6k
Christine A. Iacobuzio–Donahue United States 87 13.3k 0.8× 17.3k 1.1× 4.3k 0.6× 2.9k 0.4× 9.1k 2.0× 285 29.5k
Jessica Zucman‐Rossi France 82 13.9k 0.8× 7.2k 0.5× 7.7k 1.0× 6.4k 1.0× 7.8k 1.7× 322 31.8k
Jonathan Said United States 73 8.5k 0.5× 8.2k 0.5× 5.2k 0.7× 2.9k 0.5× 3.5k 0.7× 370 20.5k

Countries citing papers authored by Charles M. Rudin

Since Specialization
Citations

This map shows the geographic impact of Charles M. Rudin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles M. Rudin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles M. Rudin more than expected).

Fields of papers citing papers by Charles M. Rudin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles M. Rudin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles M. Rudin. The network helps show where Charles M. Rudin may publish in the future.

Co-authorship network of co-authors of Charles M. Rudin

This figure shows the co-authorship network connecting the top 25 collaborators of Charles M. Rudin. A scholar is included among the top collaborators of Charles M. Rudin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles M. Rudin. Charles M. Rudin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ireland, Abbie S., M. Weber, L. Zuo, et al.. (2025). Basal cell of origin resolves neuroendocrine–tuft lineage plasticity in cancer. Nature. 647(8088). 257–267. 4 indexed citations
2.
Augert, Arnaud, et al.. (2021). Protein neddylation as a therapeutic target in pulmonary and extrapulmonary small cell carcinomas. Genes & Development. 35(11-12). 870–887. 9 indexed citations
3.
Choudhury, Noura J., Adam J. Schoenfeld, Jessica Flynn, et al.. (2021). Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions. Clinical Cancer Research. 27(10). 2920–2927. 47 indexed citations
4.
Li, Chuan, Wen‐Yang Lin, Hira Rizvi, et al.. (2021). Quantitative In Vivo Analyses Reveal a Complex Pharmacogenomic Landscape in Lung Adenocarcinoma. Cancer Research. 81(17). 4570–4580. 10 indexed citations
5.
Paik, Paul K., Rachel K. Kim, Linda S. Ahn, et al.. (2020). A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers. Clinical Cancer Research. 26(8). 1796–1802. 10 indexed citations
6.
Madajewski, Brian, Feng Chen, Barney Yoo, et al.. (2020). Molecular Engineering of Ultrasmall Silica Nanoparticle–Drug Conjugates as Lung Cancer Therapeutics. Clinical Cancer Research. 26(20). 5424–5437. 17 indexed citations
7.
Juthani, Rupa, Brian Madajewski, Barney Yoo, et al.. (2019). Ultrasmall Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor Model. Clinical Cancer Research. 26(1). 147–158. 71 indexed citations
8.
Morgensztern, Daniel, Benjamin Besse, Laurent Greillier, et al.. (2019). Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study. Clinical Cancer Research. 25(23). 6958–6966. 229 indexed citations
9.
Devarakonda, Siddhartha, Sumithra Sankararaman, Brett H. Herzog, et al.. (2019). Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations. Clinical Cancer Research. 25(20). 6119–6126. 41 indexed citations
10.
Santini, Fernando C., Hira Rizvi, Andrew J. Plodkowski, et al.. (2018). Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC. Cancer Immunology Research. 6(9). 1093–1099. 263 indexed citations
11.
Arbour, Kathryn C., Hyunjae R. Kim, Jordan Dienstag, et al.. (2017). Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS -Mutant Non–Small Cell Lung Cancer. Clinical Cancer Research. 24(2). 334–340. 317 indexed citations
12.
Cooper, Jonathan M., Qingwen Xu, Lü Zhou, et al.. (2017). Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss–Driven Tumorigenesis. Molecular Cancer Therapeutics. 16(8). 1693–1704. 33 indexed citations
13.
Paik, Paul K., Alexander Drilon, Pang‐Dian Fan, et al.. (2015). Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping. Cancer Discovery. 5(8). 842–849. 423 indexed citations breakdown →
14.
Lin, Luping, Saurabh Asthana, Elton Chan, et al.. (2014). Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proceedings of the National Academy of Sciences. 111(7). E748–57. 73 indexed citations
15.
Kamat, Chandrashekhar D., Ron B. Shmueli, Nick Connis, et al.. (2013). Poly(β-amino ester) Nanoparticle Delivery of TP53 Has Activity against Small Cell Lung Cancer In Vitro and In Vivo. Molecular Cancer Therapeutics. 12(4). 405–415. 41 indexed citations
16.
Zinn, Rebekah L., Eric E. Gardner, Luigi Marchionni, et al.. (2013). ERK Phosphorylation Is Predictive of Resistance to IGF-1R Inhibition in Small Cell Lung Cancer. Molecular Cancer Therapeutics. 12(6). 1131–1139. 33 indexed citations
17.
Sekulić, Aleksandar, Michael R. Migden, Anthony E. Oro, et al.. (2012). Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma. New England Journal of Medicine. 366(23). 2171–2179. 1011 indexed citations breakdown →
18.
Graham, Richard, Bert L. Lum, Sravanthi Cheeti, et al.. (2011). Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein Binding. Clinical Cancer Research. 17(8). 2512–2520. 97 indexed citations
19.
Samet, Jonathan M., Érika Ávila-Tang, Paolo Boffetta, et al.. (2009). Lung Cancer in Never Smokers: Clinical Epidemiology and Environmental Risk Factors. Clinical Cancer Research. 15(18). 5626–5645. 394 indexed citations
20.
Rudin, Charles M., Érika Ávila-Tang, Curtis C. Harris, et al.. (2009). Lung Cancer in Never Smokers: Molecular Profiles and Therapeutic Implications. Clinical Cancer Research. 15(18). 5646–5661. 123 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Godefridus J. Peters Breakdown of academic impact, for papers by Manuel Hidalgo Breakdown of academic impact, for papers by Daniel D. Von Hoff Breakdown of academic impact, for papers by Ming‐Sound Tsao Breakdown of academic impact, for papers by Fadlo R. Khuri Breakdown of academic impact, for papers by Aldo Scarpa Breakdown of academic impact, for papers by Richard A. Scolyer Breakdown of academic impact, for papers by Christine A. Iacobuzio–Donahue Breakdown of academic impact, for papers by Jessica Zucman‐Rossi Breakdown of academic impact, for papers by Jonathan Said
Rankless by CCL
2026